RATIONALE: Lymphangioleiomyomatosis, a cystic lung disease of women, is characterized by proliferation of smooth muscle-like lymphangioleiomyomatosis cells, which possess mutations in the tuberous sclerosis complex genes, TSC1/TSC2. Growth factors involved in lymphangioleiomyomatosis cell proliferation are unknown. Prolactin, an important reproductive hormone in women, is known to promote cell proliferation and survival in other tissues. OBJECTIVES: To determine the role of prolactin in signaling and proliferation in lymphangioleiomyomatosis. METHODS: Prolactin levels in the sera of patients with lymphangioleiomyomatosis were correlated with clinical status. Components of prolactin signal transduction pathways were assessed in lymphangioleiomyomatosis lesions from human lung explants by real-time reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. Prolactin effects on proliferation and signaling were quantified in tuberin-deficient and tuberin-expressing rat cells in vitro. MEASUREMENTS AND MAIN RESULTS: Higher prolactin levels in the sera of patients with lymphangioleiomyomatosis were associated with a faster rate of decline in FEV(1) and an increased history of pneumothorax (P < 0.01). Higher levels of prolactin and prolactin receptor mRNA and immunoreactivity were found in lymphangioleiomyomatosis lesions when compared with vascular smooth muscle cells in the same region of tissue. This was accompanied by evidence of activation of signal transducer and activator of transcription-1 (STAT1), STAT3, p44/42, and p38 mitogen-activated protein kinase. Tsc2(-/-) Eker rat embryonic fibroblasts expressed more prolactin receptor than did Tsc2(+/+) cells, and responded to prolactin with increased proliferation and activation of the same signaling pathways seen in vivo. CONCLUSIONS: Prolactin may be an important growth factor in the pathogenesis of lymphangioleiomyomatosis.
RATIONALE: Lymphangioleiomyomatosis, a cystic lung disease of women, is characterized by proliferation of smooth muscle-like lymphangioleiomyomatosis cells, which possess mutations in the tuberous sclerosis complex genes, TSC1/TSC2. Growth factors involved in lymphangioleiomyomatosis cell proliferation are unknown. Prolactin, an important reproductive hormone in women, is known to promote cell proliferation and survival in other tissues. OBJECTIVES: To determine the role of prolactin in signaling and proliferation in lymphangioleiomyomatosis. METHODS:Prolactin levels in the sera of patients with lymphangioleiomyomatosis were correlated with clinical status. Components of prolactin signal transduction pathways were assessed in lymphangioleiomyomatosis lesions from human lung explants by real-time reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. Prolactin effects on proliferation and signaling were quantified in tuberin-deficient and tuberin-expressing rat cells in vitro. MEASUREMENTS AND MAIN RESULTS: Higher prolactin levels in the sera of patients with lymphangioleiomyomatosis were associated with a faster rate of decline in FEV(1) and an increased history of pneumothorax (P < 0.01). Higher levels of prolactin and prolactin receptor mRNA and immunoreactivity were found in lymphangioleiomyomatosis lesions when compared with vascular smooth muscle cells in the same region of tissue. This was accompanied by evidence of activation of signal transducer and activator of transcription-1 (STAT1), STAT3, p44/42, and p38 mitogen-activated protein kinase. Tsc2(-/-) Eker rat embryonic fibroblasts expressed more prolactin receptor than did Tsc2(+/+) cells, and responded to prolactin with increased proliferation and activation of the same signaling pathways seen in vivo. CONCLUSIONS:Prolactin may be an important growth factor in the pathogenesis of lymphangioleiomyomatosis.
Authors: Dunyong Tan; David A Johnson; Wei Wu; Lingfang Zeng; Yen Hao Chen; Wen Y Chen; Barbara K Vonderhaar; Ameae M Walker Journal: Mol Endocrinol Date: 2005-02-03
Authors: Shelley S Tworoger; A Heather Eliassen; Bernard Rosner; Patrick Sluss; Susan E Hankinson Journal: Cancer Res Date: 2004-09-15 Impact factor: 12.701
Authors: Wendy K Steagall; Connie G Glasgow; Olanda M Hathaway; Nilo A Avila; Angelo M Taveira-Dasilva; Antoinette Rabel; Mario P Stylianou; Jing-Ping Lin; Xiaoling Chen; Joel Moss Journal: Am J Physiol Lung Cell Mol Physiol Date: 2007-07-06 Impact factor: 5.464
Authors: Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss Journal: Am J Respir Cell Mol Biol Date: 2018-06 Impact factor: 6.914
Authors: Minzhe Guo; Jane J Yu; Anne Karina Perl; Kathryn A Wikenheiser-Brokamp; Matt Riccetti; Erik Y Zhang; Parvathi Sudha; Mike Adam; Andrew Potter; Elizabeth J Kopras; Krinio Giannikou; S Steven Potter; Sue Sherman; Stephen R Hammes; David J Kwiatkowski; Jeffrey A Whitsett; Francis X McCormack; Yan Xu Journal: Am J Respir Crit Care Med Date: 2020-11-15 Impact factor: 30.528
Authors: Carmen Herranz; Francesca Mateo; Alexandra Baiges; Gorka Ruiz de Garibay; Alexandra Junza; Simon R Johnson; Suzanne Miller; Nadia García; Jordi Capellades; Antonio Gómez; August Vidal; Luis Palomero; Roderic Espín; Ana I Extremera; Eline Blommaert; Eva Revilla-López; Berta Saez; Susana Gómez-Ollés; Julio Ancochea; Claudia Valenzuela; Tamara Alonso; Piedad Ussetti; Rosalía Laporta; Antoni Xaubet; José A Rodríguez-Portal; Ana Montes-Worboys; Carlos Machahua; Jaume Bordas; Javier A Menendez; Josep M Cruzado; Roser Guiteras; Christophe Bontoux; Concettina La Motta; Aleix Noguera-Castells; Mario Mancino; Enrique Lastra; Raúl Rigo-Bonnin; Jose C Perales; Francesc Viñals; Alvaro Lahiguera; Xiaohu Zhang; Daniel Cuadras; Coline H M van Moorsel; Joanne J van der Vis; Marian J R Quanjel; Harilaos Filippakis; Razq Hakem; Chiara Gorrini; Marc Ferrer; Aslihan Ugun-Klusek; Ellen Billett; Elżbieta Radzikowska; Álvaro Casanova; María Molina-Molina; Antonio Roman; Oscar Yanes; Miquel A Pujana Journal: EMBO Mol Med Date: 2021-08-11 Impact factor: 12.137